The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

According to website ScienceInsider, GlaxoSmithKline (NYSE: GSK) aims to have 24,000 doses of its vaccine ready for efficacy trials in January. It is mulling two trials.

Ripley Ballou, the leader of the GSK Ebola project, explained to ScienceInsider: “One of the trials may fail for logistics reasons,” he explained. “We only have one shot to get this right.”

Bailou is worried about the stability of the West African nations as well as the trials.

“The thing that is going to have the biggest impact is what is happening to the trajectory of the epidemic curve,” he said. “If you progress the current trends 2 months into the future are we still in an environment where you can even consider doing a trial?”

Meanwhile, Forbes noted that in an interview with the BBC, that other vaccine production could be hit if an Ebola vaccine were to be produced in mass quantities.

“At the same time we have to be able to manufacture the vaccine at doses that would be consistent with general use, and that’s going to take well into 2016 to be able to do that,” he said. “I don’t think this [vaccine] can be seen as the primary answer to this particular outbreak. If it does work then to be able to be prepared so that we don’t have to go through this again in five years, or whenever the next epidemic is going to break out.”

But for now, GSK continues to ramp up vaccine for testing. 

“If it cranks up production to full capacity before the those trials are complete, the company could have 230,000 doses available in April, and then could steadily increase capacity to produce more than 1 million doses a month by December 2015,” ScienceInsider said, citing documents it obtained from an WHO meeting earlier this week. 

The news Friday came after a doctor in New York City was diagnosed with Ebola. He had treated Ebola victims in Africa.

Paul Allen’s Donation

Meanwhile, Billionaire Paul Allen, co-founder of Microsoft, says he’ll contribute at least $100 million to the fight against Ebola.

The Bill and Melinda Gates Foundation also has pledged support and research. Allen and Bill Gates launched Microsoft.

Allen said Thursday that among the initiatives he’s supporting is the development of two medevac containment units that the U.S. State Department can use to safely evacuate health workers who become infected.

Allen said he’s working with the World Health Organization to increase its capacity for handling the logistics of transporting international aid workers, and he’s establishing a fund to help cover the costs of emergency transportation of the workers.

Money will also go to the University of Massachusetts Medical School to help provide decontamination and lab equipment to Liberian hospitals, as well as community outreach and education in Liberia.

Allen’s foundation previously pledged $26.5 million. He’s urging people to give to the cause at .

Vaccine “Not a Magic Bullet”

On Friday, the WHO warned it’s not clear whether any of these will work against the deadly virus that has already killed at least 4,877 people this year in West Africa.

Dr. Marie-Paule Kieny from the U.N. health agency told reporters that those doses could be available in 2015 if early tests proved that the two leading experimental vaccines are safe and provoke enough of an immune response to protect people from being infected with Ebola.

Trials of those two most advanced vaccines —one developed by GSK in cooperation with the U.S. National Institutes of Health, the other developed by the Canadian Public Health Agency and licensed to the U.S. company NewLink Genetics — have already begun in the U.S., U.K. and Mali.

Two other firms in Research Triangle Park, N.C. – Chimerix and BioCryst – also are developing vaccines. The FDA has fast-tracked the Chimerix treatment, which has been administered to at least two Ebola patients in the U.S. One later died.

“The vaccine is not the magic bullet. But when ready, they may be a good part of the effort to turn the tide of this epidemic,” Kieny said.

If early data from the ongoing tests are promising, larger trials in West Africa would offer the shot to health workers and others at high risk of catching Ebola as soon as December, Kieny said. Previously those trials weren’t starting until January.

1 Million Doses from GSK

GSK said it might be able to make about 1 million doses of their vaccine per month by the end of 2015, assuming that some logistical and regulatory hurdles can be overcome.

“The message we heard from WHO that the people fighting the epidemic will be among the first to test Ebola vaccines and treatments is exactly the one we needed to hear,” Dr. Bertrand Draguez, medical director for Doctors Without Borders, said in a statement. “This needs to be followed by a massive roll-out of vaccines to the general population once their efficacy is proven.”

Kieny also said five other possible Ebola vaccines should start being tested in March but did not specifically name them. She said Russian scientists are working on a number of vaccines including one that may be ready to go into clinical trials soon.

Johnson & Johnson said this week it would start preliminary testing of its experimental Ebola vaccine in January against a strain of Ebola that is very similar to the one causing the current outbreak in West Africa. It was not clear if that was one of the five mentioned by Kieny.

Kieny said plans to get the vaccines to West Africa had yet to be worked out, including who would pay for immunization campaigns — which weren’t planned to start before June at the earliest. Kieny said the charity Doctors Without Borders pledged to create a vaccine fund and other organizations, including the World Bank, might help buy the vaccines.

She also acknowledged that, given the speed at which these experimental vaccines are being rolled out, “there will certainly not be as much known in terms of their safety as would be normal.” Kieny said Britain had proposed creating a fund that would offload liability from pharmaceutical companies in case any bad side effects emerge from the shots.

GSK operates its North American headquarters in RTP.